Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13380553 | 0.86 | OPRM1 (0.57) | OPRM1OPRL1EPHX1KDM4EMAPT | |
| SCHEMBL13380625 | 0.86 | OPRM1 (0.57) | OPRM1OPRL1EPHX1KDM4EMAPT | |
| SCHEMBL1929076 | 0.83 | OPRM1 (0.54) | OPRM1OPRL1THRBTP53 | |
| SCHEMBL4424598 | 0.82 | OPRM1 (0.45) | OPRM1OPRL1 | |
| SCHEMBL1930034 | 0.80 | EPHX1 (0.48) | EPHX1KDM4EMAPTTHRBHPGD | |
| SCHEMBL1928274 | 0.77 | EPHX1 (0.45) | EPHX1KDM4EMAPTTHRBHPGD | |
| SCHEMBL1928616 | 0.76 | OPRM1 (0.45) | OPRM1OPRL1EPHX1KDM4EMAPT | |
| SCHEMBL3409479 | 0.74 | EPHX1 (0.44) | EPHX1KDM4EMAPTTHRBHPGD | |
| SCHEMBL1928269 | 0.72 | EPHX1 (0.48) | EPHX1KDM4EMAPTTHRBHPGD | |
| SCHEMBL8226783 | 0.72 | OPRM1 (0.51) | OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956069-B2 | Compounds | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| US-7956069-B2 | Compounds | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| US-7956069-B2 | Compounds | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| WO-2007142583-A1 | MUSCARINIC RECEPTOR AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA. | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| US-20070287695-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | disclosed |
| US-20070287695-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | disclosed |
| US-20070287695-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287695-A1 | Novel Compounds | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRL1 2/4885EPHX1 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.